Brookline Cap M Forecasts IceCure Medical Q1 Earnings

IceCure Medical Ltd. (NASDAQ:ICCM) – Stock analysts at Brookline Cap M issued their Q1 2026 earnings per share estimates for IceCure Medical in a research report issued on Tuesday, March 17th. Brookline Cap M analyst K. Dolliver anticipates that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Cap M also issued estimates for IceCure Medical’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2030 earnings at $0.22 EPS.

Several other research analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research report on Thursday, January 22nd. Wall Street Zen raised IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $2.64.

IceCure Medical Stock Performance

NASDAQ:ICCM opened at $0.60 on Thursday. The company has a 50-day moving average of $0.63 and a 200-day moving average of $0.75. IceCure Medical has a 52 week low of $0.54 and a 52 week high of $1.50. The company has a market capitalization of $41.23 million, a price-to-earnings ratio of -2.50 and a beta of 0.29.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 248.23%. The business had revenue of $1.28 million during the quarter, compared to the consensus estimate of $1.30 million.

Hedge Funds Weigh In On IceCure Medical

Several institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in IceCure Medical in the fourth quarter worth $67,000. Virtu Financial LLC acquired a new stake in shares of IceCure Medical in the fourth quarter valued at $39,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of IceCure Medical in the fourth quarter valued at $48,000. Institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.